Each soft capsule of Metopirone® contains 250 mg of metyrapone.
Metopirone® is a diagnostic drug for testing hypothalamic-pituitary ACTH function.The metyrapone diagnostic test should be restricted to referral hospital centers.
|Where?||Restricted to referral hospital centers
Under supervision of specialists
|How?||Ambulatory basis possible||Hospitalization required|
|How many doses
|A unique dose||6 divided doses|
|Which dosage in adults?||30 mg/kg at midnight
(maximum 3 g)
|700mg every 4 hrs, for 24 hrs (total dose of 4.5 g)|
|Which dosage in children?||Same dosage as in adults||15 mg/kg (minimum 250 mg)
every 4 hrs, for 24 hrs
should be measured?
|1 blood sample:
Plasma 11‑DOC and/or ACTH levels
|3 consecutive 24‑hrs urine samples:
24‑hrs urinary 17‑OHCS and/or
|When to measure?||Early in the following morning
(7.30 am‑8.00 am)
|The day before, the day of and the day
after Metopirone® administration
Table prepared by HRA Pharma based on Metopirone USPI.
ACH: Adrenocorticotropic hormone; 11-DOC: 11-deoxycortisol; 17–OHCS: 17-hydroxycorticosteroids; 17–KGS: 17 ketogenic steroids.
The capsules should be taken with yogurt or milk
Metopirone® is an inhibitor of endogenous adrenal corticosteroid synthesis.
It reduces cortisol and corticosterone production by inhibiting the 11 β – hydroxylation reaction in the adrenal cortex.
As a consequence: compensatory rise in ACTH and increase in:
Figure prepared by HRA Pharma based on Metopirone USPI.
1. Metopirone® summary of product characteristics (USA), January 2018
2. Avgerinos PC, et al. Ann Intern Med. 1994; 121(5): 318-27